Charles Hottenstein

Q: What is Charles Hottenstein email address?

Email Charles Hottenstein at charles.hottenstein@glaxosmithkline.at. This email is the most updated Charles Hottenstein email found in 2026.

Q: How to contact Charles Hottenstein?

To contact Charles Hottenstein send an email to charles.hottenstein@glaxosmithkline.at.

Scientific Leader at GSK | Greater Philadelphia

About Charles Hottenstein

Charles Hottenstein is a seasoned Scientific Leader at GSK, where he plays a pivotal role in advancing the development and validation of regulated immunogenicity methods for large molecule protein pharmaceuticals. With a robust background in pharmacokinetics and analytical chemistry, Charles leads a dedicated scientific group that focuses on the automation of bioanalytical methods, ensuring compliance with Good Laboratory Practice (GLP) standards. His expertise in immunogenicity and biomarkers is instrumental in assessing the safety and efficacy of biopharmaceuticals, particularly in the context of clinical trials.

At GSK, Charles is currently spearheading key projects that involve the integration of cutting-edge technologies to enhance the accuracy and efficiency of drug concentration bioanalysis. His leadership not only fosters innovation but also cultivates a collaborative environment where team members can thrive and contribute to the overarching goals of drug development. His proficiency in high-performance liquid chromatography (HPLC) and drug metabolism and pharmacokinetics (DMPK) further underscores his commitment to delivering high-quality results that meet regulatory expectations.

Charles holds a Bachelor’s degree in Biology from the University of Delaware, which laid the foundation for his extensive career in the life sciences sector. His ability to navigate complex scientific challenges and drive projects from conception to completion makes him a valuable asset to GSK and the broader pharmaceutical industry. Through his work, Charles continues to contribute to the advancement of biopharmaceuticals, ultimately improving patient outcomes and fostering innovation in drug development.

Charles Hottenstein Work